On April 11, Janet Linn led and moderated the panel “Will the mifepristone decision redefine standing to challenge FDA drug approvals?” for the New York State Bar Association Food Drug & Cosmetic Law Section Spring Meeting. The panel discussed the FDA Supreme Court case regarding mifepristone and how the FDA’s process for drug approval impacts the healthcare and life science legal community. Learn more here.